Loading
A phase 2 trial in lung cancer, run by Konkuk University Medical Center, now recruiting.
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy is a phase 2, interventional study registered as NCT05469022 by Konkuk University Medical Center, with a registry enrolment figure of 40 participants, started 2022-05-19 and due to reach its primary completion in 2024-05-19. Interventions recorded: Neoadjuvant lazertinib. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Objective response rate. Lung eligibility wording from the registry: "Patients with suspected lung cancer on chest CT findings". Sites: South Korea. No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.